Delivery Order SPE2DB22D1202-SPE2DB25FUYS5
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,293.84 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 ml auto-injector units. The contract is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in the same municipality....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies, with a ceiling value of $1,314.73 under a firm fixed-price arrangement. The contract was competitively awarded without set-aside provisions and is due for completion by September 9, 2025. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $1,436.03 delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Xyosted 75 mg/0.5 ml auto-injector units. The contract is a firm fixed-price delivery order with an ultimate completion date of June 2, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal medical procurement vendor specializing in...
- The Defense Logistics Agency awarded a $1,270.28 firm fixed price delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies, with an ultimate completion date of July 28, 2025. This non-set-aside contract represents a single delivery order fulfillment under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The delivery...
- The Defense Logistics Agency awarded a $1,317.52 delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for Xyosted 50 mg/0.5 mL auto-injector units with a completion date of June 20, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and is to be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. Xyosted is a testosterone replacement therapy product delivered via auto-injector, supporting the agency's...
- The Defense Logistics Agency awarded a delivery order valued at $1,248.08 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injectors on August 22, 2025, with completion targeted for August 25, 2025. This firm fixed-price contract represents a non-set-aside competitive award and will be fulfilled at the contractor's corporate office location in Conshohocken, Pennsylvania. Xyosted is a testosterone replacement therapy product delivered via auto-injector, addressing pharmaceutical...
- The Defense Logistics Agency awarded a $1,752.22 delivery order to AmerisourceBergen Drug Corp for Xyosted 50 mg/0.5 mL auto-injectors on September 5, 2025, with completion scheduled for September 8, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract and will be performed at the contractor's Conshohocken, Pennsylvania facility. Xyosted is a testosterone replacement therapy medication delivered via auto-injector, reflecting the Defense...
- The Defense Logistics Agency awarded a delivery order valued at $1,090.66 to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Xyosted 50 mg/0.5 mL auto-injector cartridges. The contract is a firm fixed price delivery order with an ultimate completion date of September 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was made without a set-aside designation, indicating competitive selection among qualified...
- The Defense Logistics Agency awarded a delivery order valued at $2,716.10 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies, with an ultimate completion date of September 15, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is the vendor performing the work at its corporate office location in the same municipality. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $2,755.76 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 ml auto-injector supplies. This non-set-aside, firm fixed-price delivery order was executed on August 1, 2025, with an ultimate completion date of August 4, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Xyosted is a testosterone replacement therapy product used in military and federal healthcare settings to support...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FUYS5Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,152.52 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 ml auto-injector supplies, with an ultimate completion date of April 25, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for military and veteran healthcare systems through its extensive federal contract portfolio. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The underlying IDC functions as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Xyosted, a testosterone replacement therapy auto-injector, falls within the company's extensive therapeutic portfolio, which includes specialty medications, brand-name and generic drugs, and related medical supplies serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 4/24/25 |